Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
66 results about "CC chemokine" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
CCR4-specific antibody composition
InactiveUS20050287138A1Enhanced effector functionEffective treatmentImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsGlycosideComplex type
The present invention provides an antibody composition comprising an antibody molecule which specifically binds to human CC chemokine receptor 4 (CCR4) and has complex type N-glycoside-linked sugar chains in the Fc region, wherein the complex type N-glycoside-linked sugar chains have a structure in which fucose is not bound to N-acetylglucosamine in the reducing end in the sugar chains; a transformant which produces the antibody composition; a process for producing the antibody composition; and a pharmaceutical composition comprising the antibody composition.
Owner:KYOWA HAKKO KOGYO CO LTD
Anti-CCR4 antibodies and methods of use therefor
InactiveUS7138117B1Nervous disorderImmunoglobulins against cell receptors/antigens/surface-determinantsCC chemokineCCR4
The present invention relates to an antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 4 (CCR4) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR4 with a ligand thereof, and to use of the antibodies and fragments in research, therapeutic, prophylactic and diagnostic methods.
Owner:MILLENNIUM PHARMA INC
Medicine containing genetically modified antibody against chemokine receptor ccr4
ActiveUS20070020263A1Fear of possible side effect may aroseEliminate side effectsOrganic active ingredientsPeptide/protein ingredientsTreatment effectCC chemokine
A medicament having a higher therapeutic effect than that provided by administration of a recombinant antibody against human CC chemokine receptor 4 or an antibody fragment thereof or an agent alone is provided.
Owner:KYOWA HAKKO KIRIN CO LTD
Human immunodeficiency virus affinity adsorption column, and preparation method and uses thereof
InactiveCN102631891ARich sourcesQuality improvementIon-exchange process apparatusOther blood circulation devicesMicrosphereHuman immunodeficiency
The invention discloses a human immunodeficiency virus (HIV) affinity adsorption column, comprising a column body and at least one activated affinity microsphere located in the column body, wherein the activated affinity microsphere is connected with a human immunodeficiency virus affinity protein, and the affinity protein can be bound with human immunodeficiency virus. The affinity protein comprises a main receptor CD4 molecule, a gp120 antibody, an auxiliary receptor CXC chemokine receptor 4 (CXCR-4) and a CC chemokine receptor 5 (CCR-5). The affinity microsphere may be a glass microsphere with the size of 1mm, a chitosan crosslinking microsphere with the diameter more than 500 microns, or a gluosan microsphere. The human immunodeficiency virus affinity adsorption column disclosed by the invention is applicable for eliminating the human immunodeficiency virus in the blood of HIV patients, and relieving and treating the immunodeficiency syndrome of HIV patients; and compared with the traditional treatment methods, the immunoadsorption column has high safety, good specificity, small toxic or side effects and good operation simplicity.
Owner:WUHAN UNIV
Chemokines that inhibit immunodeficiency virus infection and methods based thereon
InactiveUS6214540B1Prevent diseaseInhibition of replicationOrganic active ingredientsPeptide/protein ingredientsCC chemokineImmunodeficiency virus
The present invention relates to therapeutic compositions and methods for treating and preventing infection by an immunodeficiency virus, particularly HIV infection, using chemokine proteins, nucleic acids and / or derivatives or analogues thereof.
Owner:UNIV OF MARYLAND BALTIMORE
Human CDR-grafted antibody and antibody fragment thereof
InactiveUS7504104B2Inhibiting cytokine-productionReduce or deplete CCR4-expressing cellsAntipyreticAnalgesicsExtracellularHuman platelet
A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.
Owner:KYOWA HAKKO KIRIN CO LTD
Use of compounds having ccr antagonism
InactiveUS20050245537A1Effective preventionEffective treatmentBiocideSenses disorderAutoimmune conditionAutoimmune disease
It is intended to provide preventives / remedies for graft-versus-host disease and / or rejection in organ or bone marrow transplantation, rheumatoid arthritis, autoimmune diseases, allergic diseases, ischemic cerebral cell injury, myocardial infarction, chronic nephritis and arteriosclerosis. The above object can be achieved by preventives / remedies for graft-versus-host disease and / or rejection in organ or bone marrow transplantation, rheumatoid arthritis, autoimmune diseases, allergic diseases, ischemic cerebral cell injury, myocardial infarction, chronic nephritis and arteriosclerosis characterized by containing a specific compound having a CCR (CC chemokine receptor) antagonism.
Owner:TAKEDA PHARMA CO LTD +1
Anti-CCR1 antibodies and methods of use thereof
The present invention relates to an antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 1 (CCR1) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR1 with a ligand thereof, and to use of the antibodies and fragments in research, therapeutic, prophylactic and diagnostic methods.
Owner:MILLENNIUM PHARMA INC
Anti-CCR4 antibodies and methods of use therefor
The present invention relates to an antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 4 (CCR4) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR4 with a ligand thereof, and to use of the antibodies and fragments in research, therapeutic, prophylactic and diagnostic methods.
Owner:WU LIJUN +2
CC chemokine receptor 5 DNA, new animal models and therapeutic agents for HIV infection
InactiveUS7151087B2Effective in regulating monocyte accumulationEffective in regulating activationBiocidePeptide/protein ingredientsChemokine receptor D6Mammal
The susceptibility of human macrophages to human immunodeficiency virus (HIV) infection depends on cell surface expression of the human CD4 molecule and CC cytokine receptor 5. CCR5 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. CCR5 plays an essential role in the membrane fusion step of infection by some HIV isolates. The establishment of stable, nonhuman cell lines and transgenic mammals having cells that coexpress human CD4 and CCR5 provides valuable tools for the continuing research of HIV infection. In addition, antibodies which bind to CCR5, CCR5 variants, and CCR5-binding agents, capable of blocking membrane fusion between HIV and target cells represent potential anti-HIV therapeutics for macrophage-tropic strains of HIV.
Owner:UNITED STATES OF AMERICA
Neutralizing Anti-ccl20 antibodies
ActiveUS20120148592A1Reduces human CCL20-induced chemotaxisShorten the progressAntibacterial agentsFungiDiseaseHeavy chain
The present invention relates to novel humanized, chimeric and murine antibodies that have binding specificity for the human CC chemokine ligand 20 (CCL20). The present invention further relates to heavy chains and light chains of said antibodies. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a heavy chain and / or a light chain of said antibodies, and to a method of preparing said antibodies. The anti-CCL20 antibodies of the invention can be used in therapeutic applications to treat, for example, inflammatory and autoimmune disorders and cancer.
Owner:EISIA R&D MANAGEMENT CO LTD
Pharmaceutical composition comprising antibody composition which specifically binds to ccr4
A pharmaceutical composition, comprising an antibody composition which specifically binds to human CC chemokine receptor 4 (hereinafter also referred to as CCR4) and at least one medicament; and a pharmaceutical composition for administering in combination of a recombinant antibody against CCR4 and at least one medicament are required. The present invention can provide a pharmaceutical composition comprising a recombinant antibody against CCR4 and at least one medicament; and a pharmaceutical composition for administering in combination of a recombinant antibody against CCR4 and at least one medicament.
Owner:KYOWA HAKKO KIRIN CO LTD
Neutralizing anti-CCL20 antibodies
ActiveUS8491901B2Reduces human CCL20-induced chemotaxisShorten the progressAntibacterial agentsBacteriaDiseaseHeavy chain
The present invention relates to novel humanized, chimeric and murine antibodies that have binding specificity for the human CC chemokine ligand 20 (CCL20). The present invention further relates to heavy chains and light chains of said antibodies. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a heavy chain and / or a light chain of said antibodies, and to a method of preparing said antibodies. The anti-CCL20 antibodies of the invention can be used in therapeutic applications to treat, for example, inflammatory and autoimmune disorders and cancer.
Owner:EISIA R&D MANAGEMENT CO LTD
Medicament comprising recombinant antibody against chemokine receptor CCR4
ActiveUS8491902B2Fear of possible side effect may aroseEliminate side effectsOrganic active ingredientsPeptide/protein ingredientsCC chemokineAntibody fragments
Owner:KYOWA HAKKO KIRIN CO LTD
Antibodies
InactiveCN102482355AInhibit bindingBinding does not inhibitAntibacterial agentsSenses disorderEpitopeMacrophage-Derived Chemokine
The present invention provides antibodies which bind to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and which are capable of inhibiting the binding of macrophage-derived chemokine (MDC) and / or thymus and activation regulated chemokine (TARC) to CCR4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.
Owner:CANCER RES TECH LTD
CCL27 polypeptides
Owner:MERCK SHARP & DOHME CORP
Methods of inhibiting chemokine binding to chemokine receptors
InactiveUS7488717B2Modulate effectImprove bindingBiocideAntipyreticBiological interactionChemokine receptor binding
Novel peptides or peptidomimetic agents or small molecules for modulating the biological effect of a chemokine. According to the present invention, the therapeutic agents preferably are endowed with the capacity to bind to certain chemokines in order to modulate the biological interaction between the target ligand, chemokine, and the respective target receptor, chemokine receptor. These peptides may be described as agonist ligands or antagonists. Next, preferably certain peptides share consensus sequences are described which characterize the families or categories of these modulator peptides.
Owner:BIOKINE THERAPEUTICS LTD
Antikine antibodies that bind to multiple CC chemokines
An antikine antibody binds to two, three, four, five or more CC chemokines, such as RANTES / CCL5, MIP-1α / CCL3, MIP-1β / CCL4, or MCP-1 / CCL2. Methods for affinity maturation and humanization of antikine antibodies as well as the production of hybridoma cell lines producing antikine antibodies by sequential immunization are also disclosed.
Owner:VLST +1
Novel cc-chemokine antagonists
A novel CC-chemokine binding protein is isolated from the saliva of Rhipicephalus sanguineus. Compounds prepared in accordance with the present invention can be used as anti-inflammatory compounds and in the treatment or prevention of CC-chemokine-related diseases.
Owner:MERCK SERONO SA
Cc-chemokine mutants against liver diseases
InactiveUS20060228327A1Counteracts liver fibrotic injuryImprove suppression propertiesNervous disorderPeptide/protein ingredientsAutoimmune conditionMedicine
CC-Chemokine mutants having reduced Glycosaminoglycans (GAG)-binding properties are effective against liver fibrotic inflammatory and / or autoimmune diseases. Particularly preferred are the mutants of CCL5 / RANTES having reduced GAG-binding properties.
Owner:MERCK SERONO SA
Anti CCR4 antibodies and uses thereof
InactiveCN103328513AInhibit bindingBinding does not inhibitAntibacterial agentsSenses disorderEpitopeMacrophage-Derived Chemokine
The present disclosure provides antibodies which bind to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and which are capable of inhibiting the binding of macrophage-derived chemokine (MDC) and / or thymus and activation regulated chemokine (TARC) to CCR4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.
Owner:CANCER RES TECH LTD
Method of depleting regulatory T cell
InactiveUS20060034841A1Excellent therapeutic methodGood effectAntipyreticAnalgesicsDiseaseRegulatory T cell
The present invention relates to the method for depleting in vivo regulatory T cell, the method for suppressing IL-10 producing activity of regulatory T cell, the method for treating diseases in which pathologic conditions are deteriorated by regulatory T cell and the method for enhancing tumor immunity which comprises administering to a patient a monoclonal antibody which specifically binds to human CC chemokine 4 (CCR4) or the antibody fragment thereof.
Owner:KYOWA HAKKO KIRIN CO LTD
Bivalent Ligands for the Treatment of Neurological Disorders
InactiveUS20140357656A1Avoids drug-drug interactionAttenuated and eliminatedBiocideNervous disorderDiseaseNervous system
Bivalent ligands that contain two pharmacophores linked through a spacer, one of which interacts with the μ-opioid receptor (MOR) and the other of which interacts with the co-receptor CC chemokine receptor 5 (CCR5), are used for the treatment of neurological disorders such as those associated with AIDS.
Owner:VIRGINIA COMMONWEALTH UNIV
Antagonists of cxcr3-binding cxc chemokines
InactiveUS7541435B2Reduced tendency to interactAntibacterial agentsPeptide/protein ingredientsAutoimmune diseaseNon conservative
Owner:MERCK SERONO SA
Cc-Chemokine Binding Tick Proteins
A novel CC-chemokine binding protein is isolated from the saliva of Rhipicephalus sanguineus. Compounds prepared in accordance with the present invention can be used as anti-inflammatory compounds and in the treatment or prevention of CC-chemokine-related diseases.
Owner:MERCK SERONO SA
Preventives for hiv infection
It is intended to provide a novel drug which exhibits an excellent effect of preventing HIV infection in transfusing blood and using a blood preparation. This object can be achieved by a preventive for HIV infection in transfusing blood and using a blood prepartion characterized by containing a compound having an antagonism to a CC chemokine receptor (preferably antagonism to CCR5 and / or CCR2).
Owner:TAKEDA PHARMA CO LTD +1
Chemokine mutants acting as chemokine antagonists
Mutants of specific CC-chemokines containing a non-conservative substitution in a conserved consensus sequence act as CC-chemokine antagonists, and can be effectively used in the treatment of autoimmune and inflammatory diseases, cancers, and viral or bacterial infections. Particularly preferred are the RANTES / CCL5 mutants having the amino acid sequence of SEQ ID NO: 1, 2, 3, or 4.
Owner:MERCK SERONO SA
Application of compound in preparing anti-mammary cancer medicament aiming at CCL (CC chemokine ligand) 18 target
The invention provides application of a compound in preparing an anti-mammary cancer medicament aiming at CCL (CC chemokine ligand)18 target. The compound is glycinate with protection radical and can be used as the anti-mammary cancer medicament aiming at the CCL18 target. The structural formula of the compound is shown as formula I. The invention also provides an anti-mammary cancer medicament, wherein the medicament contains effective dose of a compound with a structural formula shown in the formula I. The invention provides the application of the glycinate compound with protection radical shown as the formula I aiming at the CCL18 target in preparing the anti-mammary cancer medicament, and provides a new medicament for treating the mammary cancer.
Owner:SUN YAT SEN UNIV
Inference sequence capable of inhibiting diabetes mellitus type I CCR5 (CC-chemokine receptor 5) gene expression as well as recombinant vector and application thereof
InactiveCN104059918AAffect secretionBlock processMetabolism disorderGenetic material ingredientsTh2 cytokinesHIV receptor
The invention belongs to the technical field of genetic engineering and specifically relates to an inference sequence capable of inhibiting diabetes mellitus type I specificity-related gene expression as well as a recombinant vector thereof and an application of the recombinant vector in preparing a medicine for treating diabetes mellitus type I. The recombinant vector constructed by the inference sequence is used for transfecting mouse T lymphocytes, so that secretion of Th1 / Th2 cell factors can be affected, and therefore, the recombinant vector plays an important role in insulitis at a prediabetic state, and blocks a process of the diabetes mellitus type I. The invention provides a novel means for treating the diabetes mellitus type I.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Chemokine mutants acting as chemokine antagonists
Mutants of specific CC-chemokines containing a non-conservative substitution in a conserved consensus sequence act as CC-chemokine antagonists, and can be effectively used in the treatment of autoimmune and inflammatory diseases, cancers, and viral or bacterial infections. Particularly preferred are the RANTES / CCL5 mutants having the amino acid sequence of SEQ ID NO: 1, 2, 3, or 4.
Owner:MERCK SERONO SA
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com